skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
Carbon C-14 Dacomitinib (Code C88339)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Carbon C-14 Dacomitinib

Definition: A radioconjugate consisting of an orally bioavailable small-molecule inhibitor of the epidermal growth factor receptor (erbB or HER) family of tyrosine kinases radiolabeled with carbon-14 with potential antineoplastic and beta-emitting radioisotope activity. PF-00299804 specifically and irreversibly binds to and inhibits human Her-1, Her-2, and Her-4, resulting in the proliferation inhibition and apoptosis of tumor cells that overexpress these receptors. The HER receptor family of tyrosine kinases, often overexpressed by a variety of tumor cell types, may contribute to tumor cell proliferation, differentiation, migration, and survival. PF-00299804 radiolabeled with carbon C-14 may be used as a radiotracer in pharmacological studies of PF-00299804 metabolism.

Label: Carbon C-14 Dacomitinib

NCI Thesaurus Code: C88339 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL413604  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Carbon C-14 Dacomitinib
Carbon C 14 PF-00299804

External Source Codes: 
PDQ Closed Trial Search ID 662740
PDQ Open Trial Search ID 662740 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C88339
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom